Clinical Trials Directory

Trials / Conditions / Oral Contraceptive

Oral Contraceptive

14 registered clinical trials studyying Oral Contraceptive — 1 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingSocial Media Usage in Adolescent Girls
NCT06426459
International Research Training Group 2804—
UnknownEvaluation of Hormonal Contraceptive Treatments in Obese Women
NCT02398903
Assistance Publique - Hôpitaux de Paris—
UnknownStudy Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
NCT02021097
Regenex Pharmaceutical, ChinaPhase 3
CompletedA Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healt
NCT01388491
Teva Branded Pharmaceutical Products R&D, Inc.Phase 2
CompletedOral Contraceptive (OC) Estrogen Dose and Breast Proliferation
NCT01318005
University of Southern CaliforniaN/A
CompletedA Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Cont
NCT01291004
Teva Branded Pharmaceutical Products R&D, Inc.Phase 1
CompletedA Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parame
NCT01252186
Teva Women's HealthPhase 2
CompletedComparative Trial in Hormone Withdrawal Associated Symptoms
NCT01076582
BayerPhase 3
CompletedEffect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
NCT00778609
BayerPhase 3
CompletedTMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
NCT00739622
Tibotec Pharmaceuticals, IrelandPhase 1
CompletedOral Contraceptive (OC) Progestin Dose and Breast Proliferation
NCT00972439
University of Southern CaliforniaN/A
CompletedValette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition
NCT00471991
BayerPhase 2
CompletedBleeding Pattern Study
NCT00302666
BayerPhase 3
CompletedStudy Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception
NCT00248963
Wyeth is now a wholly owned subsidiary of PfizerPhase 3